Medtronic recently saw a substantial price movement, climbing 10% over the last quarter. This period was marked by the release of promising five-year data from the Evolut Low Risk Trial, which ...

It was tested on patients with a severe heart valve disorder. On Sunday, Medtronic published five-year data from a low-risk clinical trial of its Evolut transcatheter aortic valve replacement ...

Medtronic’s system exhibited “durable” clinical results and “strong” valve performance. Credit: JHVEPhoto / Shutterstock. Medtronic has reported late-breaking data from the randomised Evolut Low Risk ...

GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the ...

The Simplici-T ® Annuloplasty System offers a first-of-its-kind approach to mitral and tricuspid valve repair. It is the first flexible band to eliminate the need for traditional sizing ...

GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the ...

The first-ever pacemaker to include Managed Ventricular Pacing (MVP®), the EnRhythm™ Pacing System promotes intrinsic conduction and is clinically proven to significantly reduce unnecessary ...

Medtronic (MDT) announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut transcatheter aortic valve replacement, TAVR, system ...

compared to the Medtronic Arctic Front Advance cardiac cryoablation catheter. Boston Scientific said in a news release that Farapulse significantly reduced AA recurrence compared to Arctic Front ...